53P Baseline PET/CT deep radiomics signature apply for identifying bevacizumab sensitivity of RAS-mutant colorectal cancer liver metastases patients

Abstract

Bevacizumab has significantly improved the resectability, response rate and survival of patients with RAS-mutant colorectal cancer liver metastases (CRLM). However, more than half of these patients were insensitive to bevacizumab therapy. Identification of patients who are sensitive to bevacizumab therapy may improve the response rate and reduce adverse events. In this study, we aimed to construct and validate a PET/CT deep radiomics signature to predict bevacizumab efficacy in initially unresectable RAS-mutant CRLM patients.